Financing ·
On June 24, 2026, 4D Molecular Therapeutics, Inc. entered into a Loan and Security Agreement with Hercules Capital…
FDMT4D Molecular Therapeutics, Inc.
On June 24, 2026, 4D Molecular Therapeutics, Inc. entered into a Loan and Security Agreement with Hercules Capital, Inc. for a senior secured term loan facility of up to $200.0 million. The facility matures on June 1, 2031, and includes a $20.0 million Tranche 1A loan drawn on the closing date, alongside several other tranches subject to milestones or discretion. Interest rates are floating, based on the prime rate plus a spread of 2.00% or 2.50%, with a floor of 8.75% or 9.25%. The agreement includes minimum cash covenants and performance covenants tied to FDA approval or revenue targets. The debt is secured by substantially all company assets, including intellectual property. 4D Molecular Therapeutics is a biotechnology company focused on developing molecular medicines.